Case Report {#sec1_1}
===========

A 33-year-old woman presented with an itchy, livid red massive infiltrated tumor, sharply demarcated and limited to the red part of her red-, black-, and green-colored tattoo 9 months after the tattooing procedure (Fig. [1a](#F1){ref-type="fig"}).

The histopathological examination of the lesion revealed pronounced pseudoepitheliomatous hyperplasia with spongiosis, and focal necrosis of the epidermis. In the dermis, there was an extensive and dense infiltration of small to medium-sized lymphocytes, that spanned the epidermis to the deep subcutis with focal epidermotropism and follicular tropism without large atypical cells. However, some large activated lymphocytes could be observed in the infiltrate. No germinal centers were identified. In addition, granular red pigment deposition and eosinophilic infiltration was noticed. The presence of exogenous pigment suggested the correct diagnosis (Fig. [2a](#F2){ref-type="fig"}).

Immunohistological staining of the skin biopsy (Fig. [2b](#F2){ref-type="fig"}) showed that the majority (\> 80%) of lymphocytes were CD3^+^, and approximately 50% of all CD3^+^ cells expressed CD4, and 50% expressed CD8 phenotypic markers. Less than 2% of the T cells were positive for CD30; a few CD20^+^ B cells could also be detected in the dermal infiltrate. Less than 5% of all cells expressed the proliferation marker Ki-67.

We detected no clonal rearrangement of the T cell receptor in the polymerase chain reaction (Fig. [3](#F3){ref-type="fig"}). The differential blood count and all other routine laboratory tests remained within the normal range.

Based on the typical clinical appearance and the pseudolymphomatous histological pattern, we diagnosed the patient with a tattoo-associated pseudolymphomatous reaction to red tattoo pigment.

We treated the lesions topically with mid-potency corticosteroid cream (betamethasone valerate) once daily 5 days a week for 6 weeks and every second day for 5 additional months. During treatment, we observed gradual regression of the tumors; complete remission of the lesions occurred after 6 months of treatment (Fig. [1b](#F1){ref-type="fig"}). No relapse occurred during a follow-up period of 3 years.

Discussion {#sec1_2}
==========

Pseudolymphomatous reactions are a heterogeneous group of benign T- or B-cell-rich infiltrates which histologically and/or clinically mimic cutaneous lymphoma \[[@B1]\]. Rare cases in the literature report the development of pseudolymphomatous reactions induced by tattooing \[[@B2]\]. At least 30 cases have been reported, and in most cases, the pseudolymphomatous reaction was related to the intradermal injection of red tattoo pigment \[[@B3]\]. It has been suggested that particles in tattoo pigments could act as antigens in the dermal skin layer and induce lymphoid cell proliferation, which then leads to a persistent reactive lymphocytic infiltration. However, the exact mechanism of the pathogenesis of the pseudolymphoma has yet to be defined \[[@B4], [@B5]\].

Like in most of the previously reported tattoo-associated pseudolymphomatous reactions, we also observed mostly T cells in the pseudolymphomatous infiltrate.

Interestingly, in former reports, the pseudolymphomatous reactions were also mostly confined to the red areas of the tattoo \[[@B3], [@B6]\]. Tattoo ink often contains metal compounds. Historically for reddish pigments, mercury (cinnabar) was often applied and has been suggested to enhance immunogenicity \[[@B3]\]. Previously, most authors indicated mercury as the causative agent \[[@B4], [@B7], [@B8]\]. Currently, due to regulations of the Food and Drug Agency (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA), mercury is prohibited and is no longer of major relevance for the development of pseudolymphomatous and/or allergic tattoo reactions. Here, we reported a pseudolymphomatous reaction due to the synthetic azo dye (pigment red 210, C20H10CI2N2O2). We identified pigment red 201, C20H10CI2N2O2, as a causative agent according to the information about the composition of the applied tattoo ink provided by the tattoo ink label and the tattoo studio. As the tattoo studio could not provide any ink samples for the further in vitro workup (C20H10CI2N2O2-dependent T cell proliferation and activation testing), this information should be used with caution. Tattoo ink labelling may be incorrect, and we cannot completely exclude inclusion of additional substances, other than C20H10CI2N2O2 or even mercury in the red tattoo pigment used in this case.

Although spontaneous remission of pseudolymphomatous reactions have been reported \[[@B4]\], pseudolymphomas are often difficult to treat, and the therapeutic approach is controversial (Table [1](#T1){ref-type="table"}). Treatment modalities include topical and intralesional application of glucocorticosteroids as well as surgical excision and laser therapy \[[@B7], [@B9], [@B10], [@B11], [@B12], [@B13]\]. Additionally, systemic therapy with hydroxychloroquine was effective in a case of tattoo-associated pseudolymphomatous reaction in the green part of the tattoo \[[@B8]\].

According to cases reported by other authors, surgical excision of the pseudolymphomatous reaction is the most effective treatment \[[@B7], [@B10], [@B11], [@B14], [@B15], [@B16], [@B17]\]. However, surgery may result in poor cosmetic outcome and is applicable for small areas only, and therefore its use is limited. Sepehri et al. \[[@B18]\] have recently suggested dermatome shave as a cosmetically acceptable rationale treatment modality for chronic tattoo reactions, as demonstrated in large series. Further, laser as treatment option is very disputatious, as some authors claim lasers aggravate the contact allergic reaction due to photochemical aspects \[[@B13]\]. In most of the cases reported with tattoo-associated pseudolymphomatous reaction limited to the red part of the tattoo, treatment with topical or intralesional corticosteroids did not induce remission \[[@B5], [@B12], [@B19], [@B20], [@B21], [@B22]\]. In our patient, the pseudolymphomatous lesions resolved completely under topical corticosteroids. Therefore, we suggest that in the case when the excision of the lesions may be limited due to the size of the lesions or cosmetic concerns, therapy with local corticosteroids may be tried in first line, despite the high recurrence rates reported in most cases \[[@B18]\]. For our patient, the duration of therapy with topical corticosteroids was considerably longer than in cases described by other authors. Hence, we propose that a longer duration of treatment might be sufficient to induce remission in some cases. The very low efficacy of topical corticosteroids reported in the literature might also be influenced by the fact that patients who responded to topical corticosteroids might be lost for follow-up and therefore not reported. It remains very controversial and purely speculative whether pseudolymphomatous reactions may rarely transform into malignant lymphoma \[[@B8], [@B23]\]. We and others would rather suggest considering the pseudolymphomatous reactions to tattoo pigment as severely exaggerated delayed-type hypersensitivity reactions \[[@B13]\].

The presented case highlights tattooing, particularly with red ink, as a risk factor for adverse immunological reactions such as cutaneous pseudolymphomatous reactions. These adverse tattooing-related reactions lead to both diagnostic and treatment challenges.
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![Clinical images of the pseudolymphomatous reaction on the patient\'s right lower extremity within a red part of her tattoo. **a**, **b** A red massive infiltrated tumor sharply demarcated and limited within the red part of her red-, black-, and green-colored tattoo 9 months after the tattooing procedure. **c**, **d** Complete resolution of the pseudolymphomatous reaction 2 years after the initial 6-month treatment with topical corticosteroids.](cde-0010-0162-g01){#F1}

![Histopathological and immunohistochemical analyses of a skin biopsy from the red infiltrated part of the tattoo on the patient\'s right lower leg. **a** Hematoxylin and eosin (HE): pseudolymphomatous reaction. The insert shows the exogeneous red pigment. **b** CD3 staining: approximately \> 80% of infiltrate positive. **c** CD4 staining: approximately 50% of infiltrate positive. **d** CD8 staining: approximately 50% of infiltrate positive. **e** CD30 staining: \< 2% of infiltrate positive. **f** CD20 staining: few positive cells. **g** Ki-67 staining: \< 5% of infiltrate positive. The inserts on pictures **b--d** represent the higher magnification of a given immunohistological staining.](cde-0010-0162-g02){#F2}

![Polymerase chain reaction of T cell receptors detected no T cell clonality.](cde-0010-0162-g03){#F3}

###### 

Treatment outcome in patients with pseudolymphomatous reaction to red pigment tattoo (Pub-Med)

  First author \[Ref.\], year   Sex   Age, years   Time of onset, years   Therapy                                                                      Outcome
  ----------------------------- ----- ------------ ---------------------- ---------------------------------------------------------------------------- ------------------------------------
  Muñoz \[[@B14]\], 2006        M     36           \-                     Surgical                                                                     Complete remission
  Jaehn \[[@B15]\], 2014        F     30           0.5                    Surgical                                                                     Complete remission
  Kuo \[[@B16]\], 2011          W     40           20                     Surgical                                                                     Complete remission
  Marchesi \[[@B7]\], 2012      M     35           0.5                    Surgical                                                                     Complete resolution
  Kahofer \[[@B5]\], 2003       F     34           6                      Topical corticosteroids                                                      No remission
                                                                          Surgical                                                                     Complete remission
  Camilot \[[@B17]\], 2012      F     39           0.4                    Surgical                                                                     No follow-up
  Camilot \[[@B17]\], 2012      M     46           0.3                    Surgical                                                                     No follow-up
  King \[[@B11]\], 2018         M     46           0.15                   Surgical                                                                     Complete resolution
                                                   4                      Intralesional steroids                                                       Complete remission after 1.4 years
  Shin \[[@B9]\], 2009          F     46           1                      Pulsed dye laser                                                             No remission
                                                                          Intralesional corticosteroids                                                Recurrence
                                                                                                                                                       
  Zinberg \[[@B12]\], 1982      M     28                                  Intralesional corticosteroids                                                Recurrence
  Cruz \[[@B19]\], 2010         M     30           1                      Very potent topical corticosteroids                                          No remission
  Malki \[[@B20]\], 2017        M     38           2                      Medium-potency corticosteroids                                               No remission
  Cristaudo \[[@B21]\], 2012    W     32           1                      Very potent topical corticosteroids                                          No remission
  Cristaudo \[[@B21]\], 2012    W     36           1.25                   Very potent topical corticosteroids                                          No remission
  Cristaudo \[[@B21]\], 2012    M     49           2                      Very potent topical corticosteroids                                          No remission
  Pasolini \[[@B22]\], 2011     M     34           0.15                   Very potent topical corticosteroids                                          No remission
  Tan \[[@B10]\], 2013          F     45           0.3                    Potent topical and intralesional corticosteroids                             No remission
                                                                          Ablative fractional resurfacing followed by Q-Switched Nd:YAG 532-nm laser   Complete remission
  Gutermuth \[[@B4]\], 2007     M     57           0.5                    No                                                                           Complete remission in
                                                                                                                                                       3 years
